Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis

No abstract is available for this paper.

• Publication year

  1995

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01690878PMID 8565989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper
• Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.

  1993cited by this paper
• Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia.

  1993cited by this paper
• Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient.

  1993cited by this paper
• Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.

  1992cited by this paper
• Protective effect of human granulocyte colony‐stimulating factor (hG‐CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice

  1991cited by this paper
• Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections.

  1991cited by this paper
• Protective effect of human granulocyte colony stimulating factor (hG‐CSF) on Candida, infections in normal and immunosuppressed mice

  1991cited by this paper
• Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils.

  1991cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Colony-stimulating factors and host defense.

  1989cited by this paper
• Risk factors for hospital-acquired candidemia. A matched case-control study.

  1989cited by this paper
• Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

  1989cited by this paper
• Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF.

  1989cited by this paper
• In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor

  1988cited by this paper

• Fungal infections: Immune defense, immunotherapies and vaccines.

  2023cites this paper
• Immunomodulatory Properties of Antifungal Agents on Immune Functions of the Host

  2019cites this paper
• Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species.

  2019cites this paper
• Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy

  2018cites this paper
• Study of immunological aspects of aspergillosis in mice and effect of polyene macrolide antibiotic (SJA-95) and IFN-γ: a possible role of IFN-γ as an adjunct in antifungal therapy.

  2011cites this paper
• Immunomodulatory Properties of Antifungal Agents on Phagocytic Cells

  2011cites this paper
• Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul‐Ehrlich‐Society for Chemotherapy

  2011cites this paper
• Granulocyte colony stimulating factor-induced exacerbation of fungus-related immune restoration inflammatory syndrome: a case of chronic disseminated candidiasis exacerbation.

  2010cites this paper
• Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy.

  2010cites this paper
• Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions

  2006cites this paper
• THE EFFECTS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN PRECLINICAL MODELS OF INFECTION AND ACUTE INFLAMMATION

  2005cites this paper
• Treatment of orogastrointestinal candidosis in SCID mice with (cid:143) uconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon- g

  2004cites this paper
• Effect of Granulocyte Colony-Stimulating Factor Combination Therapy on Efficacy of Posaconazole (SCH56592) in an Inhalation Model of Murine Pulmonary Aspergillosis

  2004influential citation
• Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp.

  2004cites this paper
• Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans

  2004cites this paper
• Polyene and cytokine treatment of experimental aspergillosis.

  2003cites this paper
• Immunomodulation of invasive fungal infections.

  2003cites this paper
• Potential for immune reconstitution through G-CSF treatment of HIV patients.

  2002cites this paper
• A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi.

  2001cites this paper
• Granulocyte colony-stimulating factor and other cytokines in antifungal therapy.

  2001cites this paper
• New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

  2000cites this paper
• Combined treatment: antifungal drugs with antibodies, cytokines or drugs.

  2000cites this paper
• Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection.

  2000cites this paper
• The role of murine models in the development of antifungal therapy for systemic mycoses.

  2000cites this paper
• Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma.

  2000cites this paper
• Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice.

  1999cites this paper
• Effects of the Hematoregulatory Peptide SK&F 107647 Alone and in Combination with Amphotericin B against Disseminated Candidiasis in Persistently Neutropenic Rabbits

  1999cites this paper
• Cytokines as therapy for opportunistic fungal infections.

  1998cites this paper
• Colony-stimulating factors and antibiotics---a new prospect in treating infectious diseases?

  1998cites this paper
• Cytokines and mycoses.

  1998cites this paper
• The Effects of Granulocyte Colony-Stimulating Factor (G-CSF) in Pre-Clinical Models of Infection and Acute Inflammation

  1998cites this paper
• Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice.

  1998cites this paper
• Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression

  1998cites this paper
• Staphylococcus aureus bacteraemia, Absidia corymbifera infection and probable pulmonary aspergillosis in a recipient of orthotopic liver transplantation for end stage liver disease secondary to hepatitis C.

  1997cites this paper